We test every gene in the human genome using advanced, AI-powered models of protein function to uncover new genetic programs that boost T cell persistence and resistance to immunosuppression.
By analyzing data from thousands of patient tumors, we engineer diverse receptors and deeply profile them with multimodal single-cell tools to measure both expression and tumor-killing function.
Our therapies leverage gamma delta T cells, which naturally target tumors through both innate and adaptive mechanisms and are inherently better suited for tissue infiltration.
We’re building a naturally allogeneic cell therapy that reduces time to treatment and cost—offering the scalability of a biologic with the curative potential of cell therapy.
First–in–human anticipated H1 '27
Candidate nomination anticipated H1 '27
Supported by:
